Cipla Ltd.

United States Food and Drug Administration (USFDA) has classified the inspection conducted at Cipla’s Goa manufacturing facility from September 16-17, 2019 as Official Action Indicated (OAI). The Company will work closely with the agency to comprehensively address the observations received.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.